RANI vs. CMPS, OLMA, ARCT, AURA, ATAI, GLUE, SEPN, PVLA, ATYR, and TSHA
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), Aura Biosciences (AURA), Atai Life Sciences (ATAI), Monte Rosa Therapeutics (GLUE), Septerna (SEPN), Palvella Therapeutics (PVLA), Atyr PHARMA (ATYR), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry.
Rani Therapeutics vs.
Rani Therapeutics (NASDAQ:RANI) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
COMPASS Pathways received 32 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 82.93% of users gave Rani Therapeutics an outperform vote while only 81.48% of users gave COMPASS Pathways an outperform vote.
Rani Therapeutics currently has a consensus price target of $12.33, suggesting a potential upside of 954.13%. COMPASS Pathways has a consensus price target of $20.20, suggesting a potential upside of 545.37%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rani Therapeutics is more favorable than COMPASS Pathways.
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Rani Therapeutics has higher revenue and earnings than COMPASS Pathways. COMPASS Pathways is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways' return on equity of -63.85% beat Rani Therapeutics' return on equity.
In the previous week, COMPASS Pathways had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for COMPASS Pathways and 1 mentions for Rani Therapeutics. COMPASS Pathways' average media sentiment score of 1.73 beat Rani Therapeutics' score of 0.00 indicating that COMPASS Pathways is being referred to more favorably in the news media.
Rani Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.
Summary
Rani Therapeutics beats COMPASS Pathways on 9 of the 17 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RANI) was last updated on 4/20/2025 by MarketBeat.com Staff
